Filtrer vos résultats
- 2
- 1
- 2
- 1
- 3
- 1
- 1
- 1
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trialDigestive and Liver Disease, 2022, pp.S1590-8658(22)00662-4. ⟨10.1016/j.dld.2022.08.036⟩
Article dans une revue
inserm-03986083v1
|
||
|
PO-0702: Phase I trial evaluating panitumumab in combination with chemoradiotherapy for anal cancersESTRO 36, May 2017, Vienne, Austria. , Radiotherapy and Oncology, 123 (Supplement 1), pp.S367 - S368, 2017, ESTRO 36, May 5-9, 2017, Vienna, Austria. ⟨10.1016/S0167-8140(17)31139-8⟩
Poster de conférence
hal-01685153v1
|
||
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trialEuropean Journal of Cancer, 2018, 104, pp.108-116. ⟨10.1016/j.ejca.2018.09.006⟩
Article dans une revue
hal-01960176v1
|